Superworth

Anika Therapeutics price to free cash flow ANIK

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
n/m
a sliver of free cash flow
10-year median
31.7×
10-year range
10.7× to 497×
Peer median
16.0×

Anika Therapeutics' price to free cash flow is not a meaningful number today: a multiple this high rests on a sliver of free cash flow.

On the days it had one over the last ten years, its median was 31.7×, from 10.7× in Mar 2020 to 497× in Sep 2026.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far476×42.5×497×
2025213×213×222×
2024215×215×335×
2023165×165×202×
2022187×95.7×242×
2021253×22.3×318×
202029.2×10.7×29.2×
201924.1×13.8×32.3×
201818.2×17.2×31.3×
201724.9×24.1×69.1×
201653.3×15.0×57.2×
201515.6×13.2×19.9×
201417.6×14.8×27.1×
201323.6×11.5×25.0×
201211.7×11.7×36.7×

Against its peers

Companies in Medical - Instruments & Supplies nearest Anika Therapeutics' size, closest first, today.

CompanyPrice to free cash flow
ANIKAnika Therapeuticsn/m
INFUInfuSystem12.1×
UTMDUtah Medical Products20.6×
EMBCEmbecta2.3×
PDEXPro DEX29.5×
TCMDTactile Systems Technology20.0×
MDXGMimedxn/m
MOVMovado9.8×
KEQUKewaunee Scientific8.7×
IRMDIradimed43.7×
STAAStaar Surgicaln/m
Peer median16.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Anika Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.